<a href=GSK” height=”184″ src=”https://www.pharmaceutical-technology.com/wp-content/uploads/image-digitalinsightresearch/Archive/Main/GSK3.jpg” style=”padding: 10px” width=”254″ />

GlaxoSmithKline (GSK) has submitted a supplemental new drug application (sNDA) to US Food and Drug Administration (FDA) for eltrombopag (Promacta).

GSK are seeking additional approval to treat paediatric patients over the age of six with chronic immune (idiopathic) thrombocytopenia (ITP).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The drug is being indicated for ITP patients who had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

The sNDA application was based on results from two trials in paediatric chronic ITP, the Phase III PETIT2 study (TRA115450) and Phase II PETIT study (TRA108062).

"The sNDA application was based on results from two trials in paediatric chronic ITP, the Phase III PETIT2 study (TRA115450) and Phase II PETIT study (TRA108062)."

Marketed as Promacta in the US and Revolade in the EU and the rest of the world, eltrombopag has not yet received approval or licensed anywhere worldwide for use for chronic ITP in a paediatric setting.

See Also:

ITP is characterised by a low platelet count and it affects five in 100,000 children every year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Most children with acute ITP do not require treatment or their disease clears without treatment. Approximately 30% of patients experience persistent disease at 12 months and are diagnosed with chronic ITP.

In August, the company’s sNDA was approved for Promacta (eltrombopag) to treat patients with severe aplastic anaemia (SAA) whohad an insufficient response to immunosuppressive therapy (IST).

Approval was based on results from an investigator-sponsored Phase II trial (09-H-0154) carried out by the National Heart, Lung and Blood Institute (NHLBI) at the National Institutes of Health (NIH).

Image: GlaxoSmithKline at Philadelphia. Photo: courtesy of Beyond My Ken.